Opiant Pharmaceuticals, Inc.
Opiant Pharmaceuticals, Inc. (OPNT) Stock Overview
Explore Opiant Pharmaceuticals, Inc.’s financial performance, market position, analyst ratings, and future outlook.
Key Financials
Key Financials
Market Cap
108.8M
P/E Ratio
30.58
EPS (TTM)
$-6.53
ROE
0.07%
OPNT Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of Opiant Pharmaceuticals, Inc. (OPNT) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
Our forecasting models predict significant price movements, with a 12-month target of $8.69.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of 30.58 and a market capitalization of 108.8M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.
Company Profile
Opiant Pharmaceuticals, Inc., a specialty pharmaceutical company, develops medicines for addictions and drug overdose. The company offers NARCAN nasal spray, a treatment to reverse opioid overdoses. Its pipeline of product candidates includes medicines for the treatment for opioid overdose reversal; alcohol use disorders; acute cannabinoid overdose; and opioid use disorders. The company was formerly known as Lightlake Therapeutics Inc. and changed its name to Opiant Pharmaceuticals, Inc. in January 2016. Opiant Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Santa Monica, California.
Roger Crystal
37
233 Wilshirre Boulevard, Santa Monica, CA
2007